BioStock: BioInvent’s CEO: “This year we made unprecedented progress”

2023 has undoubtedly been one of the most successful for BioInvent, if not the most successful. The company’s cancer treatment pipeline currently includes five drug candidates progressing through six clinical trials – and progress has been announced in all programmes during the year. However, in the current tough market dynamics for biotech, like many other companies, BioInvent is valued under cash. BioStock contacted CEO Martin Welschof to talk about the progress during 2023 and to learn about his expectations for next year.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2023/12/bioinvents-ceo-this-year-we-made-unprecedented-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/